Italy Pharmaceuticals & Healthcare Report Q2 2015 - New Study Released

From: Fast Market Research, Inc.
Published: Thu Apr 30 2015

SNS pharmaceutical expenditure will decline in 2015 - creating revenue pressures for drugmakers and pharmacies in Italy and increasing out-of-pocket costs for the population. In February 2015, it was announced that the public healthcare costs will be slashed by EUR2.6bn (USD2.9bn) in 2015. We note that this accounts for a large proportion of the EUR5.2bn (USD5.8bn) spending cuts announced by the government.

Headline Expenditure Projections

* Pharmaceuticals: EUR19.94bn (USD26.72bn) in 2014 to EUR19.07bn (USD20.98bn) in 2015; -4.3% in local currency terms and -21.5% in US dollar terms.
* Healthcare: EUR145.41bn (USD194.85bn) in 2014 to EUR147.28bn (USD162.01bn) in 2015; +1.3% growth in local currency terms and -16.9% in US dollar terms.

Risk/Reward Index : In our Pharmaceuticals and Healthcare Risk/Reward Index (RRIs), Italy is 13th out of the 15 markets surveyed in Western Europe. Despite being a large market, Italy is characterised by low levels of annual growth, largely due to of widespread price cuts. Additionally, the Italian economy is one of the most vulnerable economies in an already shaky eurozone. High levels of public debt, poor infrastructure and a lack of competitiveness indicate that the country will remain one of the region's laggards over the forecast period.

Full Report Details at

Key Trends And Developments

In February 2015, Europe's pharmaceutical and biotech companies filed a complaint against a new Italian law that promotes the off-label use of drugs, stating that the law is aimed solely at saving money. The European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) and the European association for bio-industries (EuropaBio) filed a complaint to the European Commission (EC) regarding the matter. The associations claim that the country's legislation is promoting the use of drugs 'for an indication for which they do not have marketing authorisation, purely for economic...

The Italy Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Italy Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Italy pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Italy, to test other views - a key input for successful budgeting and strategic business planning in the Italian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- United Arab Emirates Pharmaceuticals & Healthcare Report Q2 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q2 2015
- South Korea Pharmaceuticals & Healthcare Report Q2 2015
- Peru Pharmaceuticals & Healthcare Report Q2 2015
- Portugal Pharmaceuticals & Healthcare Report Q2 2015

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »